About Renasant Bio

Renasant Bio is developing oral small molecule therapies to address the root cause of autosomal dominant polycystic kidney disease (ADPKD). Their approach focuses on restoring the function of polycystin proteins, aiming to halt disease progression and potentially reverse cyst growth.

<problem> Autosomal dominant polycystic kidney disease (ADPKD) is a prevalent genetic disorder characterized by progressive cyst development in the kidneys, leading to organ enlargement, chronic pain, hypertension, and ultimately end-stage renal failure. Current treatment options are limited to symptom management and blood pressure control, with only one FDA-approved therapy offering modest effects on slowing disease progression. There is a significant unmet need for therapies that address the underlying cause of ADPKD and halt its relentless decline in kidney function. </problem> <solution> Renasant Bio is developing oral small molecule correctors and potentiators designed to target the root cause of ADPKD by restoring the function of polycystin 1 and 2 (PC1/2) proteins. Correctors act as molecular chaperones, stabilizing PC1/2 and promoting proper folding and trafficking to the cilia surface. Potentiators enhance ion flux by holding the polycystin channel open, thereby restoring crucial signaling pathways. These therapeutic classes can be administered as standalone treatments or in combination for synergistic effects. Preclinical data indicate that restoring PC1/2 function can not only halt disease progression but also reverse cyst growth and improve kidney function. The company aims to provide disease-modifying treatments applicable across a broad range of ADPKD mutations. </solution> <features> - Oral small molecule correctors designed to stabilize polycystin proteins and restore proper folding and trafficking. - Oral small molecule potentiators that enhance ion flux by keeping the polycystin channel open, restoring signaling pathways. - Dual-mechanism approach allowing for combination therapy of correctors and potentiators for synergistic effects. - Therapeutic candidates designed to address a broad spectrum of ADPKD-causing mutations. - Focus on restoring polycystin protein function as the underlying mechanism of action. </features> <target_audience> The primary target audience includes patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD) and the nephrology and genetics specialists who treat them. </target_audience>

What does Renasant Bio do?

Where is Renasant Bio located?

Renasant Bio is based in Berkeley, United States.

How much funding has Renasant Bio raised?

Renasant Bio has raised 54500000.

Location

Berkeley, United States

Funding

54500000

Employees

27 employees

Major Investors

5AM Ventures

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Renasant Bio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

renasantbio.com 1K+

Crunchbase

Berkeley, United States

Funding

Estimated Funding

$50M+

Major Investors

5AM Ventures

Team (25+)

No team information available.

Company Description

Problem

Autosomal dominant polycystic kidney disease (ADPKD) is a prevalent genetic disorder characterized by progressive cyst development in the kidneys, leading to organ enlargement, chronic pain, hypertension, and ultimately end-stage renal failure. Current treatment options are limited to symptom management and blood pressure control, with only one FDA-approved therapy offering modest effects on slowing disease progression. There is a significant unmet need for therapies that address the underlying cause of ADPKD and halt its relentless decline in kidney function.

Solution

Renasant Bio is developing oral small molecule correctors and potentiators designed to target the root cause of ADPKD by restoring the function of polycystin 1 and 2 (PC1/2) proteins. Correctors act as molecular chaperones, stabilizing PC1/2 and promoting proper folding and trafficking to the cilia surface. Potentiators enhance ion flux by holding the polycystin channel open, thereby restoring crucial signaling pathways. These therapeutic classes can be administered as standalone treatments or in combination for synergistic effects. Preclinical data indicate that restoring PC1/2 function can not only halt disease progression but also reverse cyst growth and improve kidney function. The company aims to provide disease-modifying treatments applicable across a broad range of ADPKD mutations.

Features

Oral small molecule correctors designed to stabilize polycystin proteins and restore proper folding and trafficking.

Oral small molecule potentiators that enhance ion flux by keeping the polycystin channel open, restoring signaling pathways.

Dual-mechanism approach allowing for combination therapy of correctors and potentiators for synergistic effects.

Therapeutic candidates designed to address a broad spectrum of ADPKD-causing mutations.

Focus on restoring polycystin protein function as the underlying mechanism of action.

Target Audience

The primary target audience includes patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD) and the nephrology and genetics specialists who treat them.